This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bhardwaj, A. Articles by Watson, J. C. Search for Related Content PubMed PubMed Citation Articles by Bhardwaj, A. Articles by Watson, J. C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB D-MANNITOL SODIUM CHLORIDE Medline Plus Health Information Transient Ischemic Attack Related Collections Animal models of human disease Acute Cerebral Infarction Other Stroke Treatment - Medical

(Stroke. 2000;31:1694.)
© 2000 American Heart Association, Inc.

Original Contributions

Hypertonic Saline Worsens Infarct Volume After Transient Focal Ischemia in Rats

Anish Bhardwaj, MD; Izumi Harukuni, MD; Stephanie J. Murphy, VMD, PhD; Nabil J. Alkayed, MD, PhD; Barbara J. Crain, MD, PhD; Raymond C. Koehler, PhD; Patricia D. Hurn, PhD Richard J. Traystman, PhD

From the Departments of Anesthesiology/Critical Care Medicine (A.B., I.H., S.J.M., N.J.A., R.C.K., P.D.H., R.J.T.), Neurology (A.B.), and Pathology (B.J.C.), Johns Hopkins University School of Medicine, Baltimore, Md.

Correspondence to Anish Bhardwaj, MD, Neuroscience Critical Care Division, Meyer 8-140, Johns Hopkins Hospital, 600 N Wolfe St, Baltimore, MD 21287. E-mail abhardwa{at}jhmi.edu

Background and Purpose—Hypertonic saline (HS) has been advocated as a hyperosmolar agent for the treatment of cerebral edema, especially after traumatic brain injury. We tested the hypothesis that continuous intravenous HS administered during reperfusion from transient focal cerebral ischemia attenuates infarct volume.

Methods—Halothane-anesthetized male Wistar rats were subjected to 2 hours of middle cerebral artery occlusion (MCAO) by the intraluminal occlusion technique. At the onset of reperfusion, rats received a 10-mL/kg intravenous bolus of 0.9% saline (SAL, n=8) or 7.5% SAL (chloride:acetate 50:50, n=8) followed by a continuous infusion for 22 hours. In a second series of experiments, ischemic damage was determined in cohorts treated with equivolumetric 3% saline (n=8) or 20% mannitol (n=8). In a third series, regional cerebral blood flow was measured ([¹⁴C]iodoantipyrine autoradiography) at 6 hours of reperfusion in 7.5%-SAL–treated (n=5) or SAL-treated (n=5) animals.

Results—In SAL rats, serum Na⁺ was 137±3 and 138±2 mEq/L (mean±SEM) at baseline and 22 hours of reperfusion, respectively. In 7.5% SAL, serum Na⁺ was 136±2 and 154±2 mEq/L at baseline and reperfusion, respectively. Physiological variables and reduction in laser-Doppler signal during MCAO and early reperfusion were not different between the 2 treatment groups. Cortical infarct volume was larger in 7.5%-SAL–treated rats (121±14 mm³; 30±3% of contralateral cortex; P<0.05) than in SAL (64±15 mm³; 16±4% of contralateral cortex). Striatal infarct volume was unchanged by HS therapy. Ipsilateral cortical tissue volume was increased relative to the contralateral side (by 26±5% with SAL; by 41±5% with 7.5% SAL). In contrast, ischemic damage was unaffected by 3%-SAL or 20%-mannitol treatment compared with SAL. Regional cerebral blood flow during reperfusion was heterogeneous in all animals, but there was no evidence of postischemic hypoperfusion or blood flow maldistribution in 7.5%-SAL–treated animals.

Conclusions—These data demonstrate that hypernatremia resulting from postischemic HS infusion worsens cortical infarct volume in transient focal cerebral ischemia. The deleterious effect is not linked to exacerbation of delayed hypoperfusion during early reperfusion (6 hours); however, blood flow defects at later recovery time points remain to be excluded. These results may have implications for HS therapy in clinical ischemic stroke.

Editorial Comment

Joe C. Watson, MD, Guest Editor

Department of Neurological Surgery University of California, Davis

This article has been cited by other articles:

				J. Bardutzky and S. Schwab Antiedema Therapy in Ischemic Stroke Stroke, November 1, 2007; 38(11): 3084 - 3094. [Abstract] [Full Text] [PDF]

				A. Chodobski Possible new mechanism underlying hypertonic saline therapy for cerebral edema J Appl Physiol, May 1, 2006; 100(5): 1437 - 1438. [Full Text] [PDF]

				Z. Zhang, T.-Y. Chen, J. R. Kirsch, T. J. K. Toung, R. J. Traystman, R. C. Koehler, P. D. Hurn, and A. Bhardwaj Kappa-Opioid Receptor Selectivity for Ischemic Neuroprotection with BRL 52537 in Rats Anesth. Analg., December 1, 2003; 97(6): 1776 - 1783. [Abstract] [Full Text] [PDF]

				T. Goyagi, T. J.K. Toung, J. R. Kirsch, R. J. Traystman, R. C. Koehler, P. D. Hurn, and A. Bhardwaj Neuroprotective {kappa}-Opioid Receptor Agonist BRL 52537 Attenuates Ischemia-Evoked Nitric Oxide Production In Vivo in Rats Stroke, June 1, 2003; 34(6): 1533 - 1538. [Abstract] [Full Text] [PDF]

				W. C. Ziai, M. A. Mirski, A. Bhardwaj, S. Schwarz, D. Georgiadis, S. Schwab, and A. Aschoff Use of Hypertonic Saline in Ischemic Stroke Stroke, April 1, 2002; 33(4): 1166 - 1167. [Full Text] [PDF]

				P. D. Mongan, J. Capacchione, J. L. Fontana, S. West, and R. Bunger Pyruvate improves cerebral metabolism during hemorrhagic shock Am J Physiol Heart Circ Physiol, August 1, 2001; 281(2): H854 - H864. [Abstract] [Full Text] [PDF]

				A. Bhardwaj, A. F. Castro III, N. J. Alkayed, P. D. Hurn, and J. R. Kirsch Anesthetic Choice of Halothane Versus Propofol: Impact on Experimental Perioperative Stroke Stroke, August 1, 2001; 32(8): 1920 - 1925. [Abstract] [Full Text] [PDF]

				R. J. Traystman, J. A. Klaus, A. C. DeVries, A. B. Shaivitz, and P. D. Hurn Anticonvulsant Lamotrigine Administered on Reperfusion Fails To Improve Experimental Stroke Outcomes Stroke, March 1, 2001; 32(3): 783 - 787. [Abstract] [Full Text] [PDF]